Hasil Pencarian (17430)
Halaman 284 / 349Reboxetine is an antidepressant drug used in the treatment of clinical depression, panic disorder and ADD/ADHD. Its mesylate (i.e. methanesulfonate) salt is sold under tradenames including Edronax, Norebox, Prolift, Solvex, Davedax or Vestra. Reboxetine has t…
REC-994 was cleared by the FDA in July, 2018 for a phase I trial for the treatment of cerebral cavernous malformation (CCM).
Recanaclotide is under investigation in clinical trial NCT01712412 (Phase 2a Study of IW-9179 to Treat Functional Dyspepsia).
Recaticimab is under investigation in clinical trial NCT06467617 (Adebrelimab Plus Chemo and Recaticimab Perioperative Treatment for Resectable NSCLC).
Receptor binding domain SARS-CoV-2 Hepatitis B surface antigen virus-like particle vaccine (RBD SARS-CoV-2 HBsAg VLP vaccine), is a virus-like particle vaccine candidate where the RBD antigen is conjugated to the hepatitis B surface antigen[A226593]. Virus-li…
Recoflavone has been used in trials studying the treatment of Acute Gastritis, Dry Eye Syndrome, and Chronic Gastritis.
Alpha 1-antitrypsin is a glycoprotein primarily produced by hepatocytes, and to a lesser extent, immune system cells. Recombinant alpha 1-antitrypsin (rAAT) is produced from yeast, which unlike commercially available forms of plasma-derived AAT, eliminates th…
Deskripsi belum tersedia.
B38-CAP is structured as a carboxypeptidase and derived from _Paenibacillus sp._ The molecule, an Angiotensin Converting Enzyme 2 (ACE2)-like enzyme, shares structural similarities to the mammalian ACE2. B38-CAP is an ACE2-like enzyme which decreases angioten…
Recombinant CD40-ligand is under investigation in clinical trial NCT00053391 (Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma).
Recombinant human kallikrein-1 is under investigation in clinical trial NCT01845064 (A Study to Evaluate the Safety and Effectiveness of DM199 in Healthy Subjects and Type 2 Diabetes Patients).
Recombinant human thrombopoietin is a full-length glycosylated cytokine produced by Chinese hamster ovary cells and is used to promote the generation of megakaryocytes and platelets.[A225691, A225696] This drug is used in the treatment of thrombocytopenia.
The Recombinant SARS-CoV-2 Vaccine was created by inserting genes of the SARS-CoV-2 spike protein’s receptor-binding domain into a baculovirus expression system[F4738, A226853]. In pre-clinical trial testing on mice, rabbits, and non-human primates, the candi…
Recombinant stabilized RSV B prefusion F antigen is one component of a bivalent respiratory syncytial virus (RSV) vaccine called Abrysvo. The vaccine comprises two antigens - the other being [recombinant stabilized RSV A prefusion F antigen] - which have been…
Recombinant stabilized RSV B prefusion F antigen is one component of a bivalent respiratory syncytial virus (RSV) vaccine called Abrysvo. The vaccine comprises two antigens - the other being [recombinant stabilized RSV A prefusion F antigen] - which have been…
Red blood cell-encapsulated L-asparaginase is [Asparaginase Escherichia coli] encapsulated inside donor-derived red blood cells, which target cancer cells capable of altering asparagine and glutamine metabolism. It is being investigated in cancers.[L44923]
Deskripsi belum tersedia.
Redasemtide is under investigation in clinical trial NCT05953480 (A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke).
Deskripsi belum tersedia.
Refanezumab is under investigation in clinical trial NCT00833989 (Safety Escalating Repeat IV, in Stroke Patients).
Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining. Manufactured by Astellas and FDA approved April 10, 2008.
Regdanvimab (CT-P59) is a recombinant human IgG1 monoclonal antibody directed at the receptor binding domain (RBD) of the SARS-CoV-2 spike protein.[L39140] It blocks the interaction between viral spike proteins and angiotensin-converting enzyme 2 (ACE2) that …
Reglitazar, an isoxazolidine-3,5-dione derivative, is being developed by Pfizer for the treatment of diabetes. It is the first non-thiazolidenedione to enter clinical trials.
Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Reg…